NY-LUXOFT-HOLDING,-INC
Luxoft Holding, Inc (NYSE:LXFT), a global IT service provider, announces the acquisition of Objective Software GmbH , a provider of software development services and IP based solutions for autonomous vehicles, Advance Driver Assisted Systems (ADAS), high-accuracy positioning, innovative mobility and smart city applications.
Objective implements its advanced technology solutions in the automotive sector, with a focus on connected cars and autonomous drive services for leading Original Equipment Manufacturers (OEMs) and suppliers.
This acquisition expands Luxoft's ADAS, Autonomous Drive and Connected Mobility practices and illustrates a commitment to meet the growing demand for these services. Upon completion of this transaction, Luxoft gains access to a range of IP-based solutions developed by Objective, including a tele-operated driving platform, cloud-based autonomous car-sharing, automotive cybersecurity solutions and a Lidar-based automated parking scanner. These solutions, combined with Objective's domain expertise, will enhance Luxoft's design, development and implementation of next-generation software that empowers our clients to succeed in the mobility revolution.
Given close synergies with our service-led model, backed by in-house application development, we anticipate opportunities to significantly scale Objective's existing projects in autonomous driving and connected mobility. In particular, the acquisition further strengthens our presence in Munich where we intend to expand software development services for highly automated driving with OEMs and Tier1s, thereby delivering software effectively across the full value chain.
"This acquisition reinforces the strong foundation on which our automotive practice has grown in recent years and future-proofs our capabilities," said Dmitry Loschinin, President and CEO of Luxoft . "Objective has established a strong footprint with major German OEMs, and we believe these synergies will allow us to deliver more strategic value to our clients. We look forward to working with Objective's team and enhancing our existing offerings, as we develop the tools that are enabling the mobility revolution."
Through Luxoft's global ecosystem of 42 delivery centers, this acquisition will expand the scalability and reach of Objective's offering within its existing footprint of leading German OEMs and their suppliers. It also strengthens Luxoft's delivery capabilities in Germany, while adding a new office in Italy.
"There is huge potential for Luxoft to grow Objective's solutions to benefit new and existing customers," said Clemens Dannheim, the co-CEO of Objective . "Both the Company's culture and like-minded approach to building advanced automotive solutions make for a well matched acquisition. With advanced connected mobility services and autonomous cars already on our streets, we wanted to take this opportunity to scale our business and effect the changes revolutionizing the automotive industry on a global scale."
About Luxoft
Luxoft (NYSE:LXFT) is a global IT service provider of innovative technology solutions that delivers measurable business outcomes to multinational companies. Its offerings encompass strategic consulting, custom software development services, and digital solution engineering. Luxoft enables companies to compete by leveraging its multi-industry expertise in the financial services, automotive, communications, and healthcare & life sciences sectors. Its managed delivery model is underpinned by a highly-educated workforce, allowing the Company to continuously innovate upwards on the technology stack to meet evolving digital challenges.
Luxoft has more than 12,900 staff across 42 cities in 21 countries within five continents, with its operating headquarters office in Zug, Switzerland. For more information, please visit www.luxoft.com .
About Objective
Objective Software GmbH is an IT company that offers advanced solutions for the future: Areas such as automotive, autonomous vehicles, teleoperated driving, high-precision positioning as well as innovative mobility or smart city applications are among the company's areas of expertise. The company's standards are high, which is why it is committed to effective and immediate action, clear goals and a visionary approach. The Objective-motor drives it: The passion and creativity of the team, coupled with excellent team spirit and organization. With over 100 employees spread over several locations in Europe, the teams offer exciting projects with global Original Equipment Manufacturers and Tier one Suppliers.
Further information about the company and its projects can be found at www.objective.de .
Forward-Looking Statements
This news release of Luxoft Holding, Inc ("Luxoft") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include information about possible or assumed future results of our business and financial condition, as well as the results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. These statements are subject to, without limitation, the risk factors discussed under the heading "Risk Factors" in Luxoft's Annual Report on Form 20-F for the year ended March 31, 2017 and other documents filed with or furnished to the Securities and Exchange Commission by Luxoft. Except as required by law, Luxoft undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this news release whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005535/en/
Contact:
Luxoft Holding, Inc
Investor Inquiries
Tracy
Krumme
Vice President, Investor Relations
212.964.9900 x2460
IR@luxoft.com
or
Media
Inquiries
Robert
Maccabe
Director, Public Relations
t: +44 (0)20 3828 2346;
m:+44 7950 517 836
Press@luxoft.com
Twitter:
@Luxoft
or
Julia
Maehner
Marketing Specialist
T: +49 89 710 501 26
Julia.maehner@objective.de
Twitter:
@objectiveSW
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom